Last reviewed · How we verify
DACOMITINIB
At a glance
| Generic name | DACOMITINIB |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2018 |
Approved indications
Common side effects
- Diarrhea
- Rash
- Paronychia
- Stomatitis
- Decreased appetite
- Dry skin
- Decreased weight
- Alopecia
- Cough
- Pruritus
- Nausea
- Palmar-plantar erythrodysesthesia syndrome
Serious adverse events
- Diarrhea
- Interstitial lung disease
- Paronychia
- Rash
- Stomatitis
- Dry skin
- Dermatitis
- Nausea
- Decreased appetite
- Decreased weight
Key clinical trials
- Korea Post Marketing Surveillance (PMS) Study of Vizimpro
- Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer (PHASE1)
- Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer
- Dacomitinib in Lung Cancer With Uncommon EGFR Mutations (PHASE2)
- A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.
- Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC (PHASE1, PHASE2)
- Phase 2 Study of Dacomitinib in NSCLC (PHASE2)
- Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DACOMITINIB CI brief — competitive landscape report
- DACOMITINIB updates RSS · CI watch RSS